该产品是授权默克制药公司于2005年。
默克制药（MRK）收购Schering-Plough（先灵葆雅），希望到2013年在新兴市场的由目前的18%上升至25%。
Since it purchased Schering-Plough, Merck has wanted to increase its sales in emerging markets from 18% to 25% by 2013.
去年下旬，默克制药公司透露其正面临与美国及加拿大税务部门的四起纠纷，这可能要使它耗资56亿美元来支付那些多余税收和利息的费用。
Late last year Merck, a drugs company, disclosed that it is facing four disputes with American and Canadian tax authorities that could cost it $5.6 billion in additional taxes and interest.
默克制药(MRK，财富500强)和Portola制药公司表示，他们将研发销售一种口服血液稀释剂，以防止心脏病患者中风。
Merck (MRK, Fortune 500) and Portola Pharmaceuticals said they will develop and market an oral blood thinner used to prevent stroke in heart patients.
投资者表示，他们也正在起诉默克制药公司。由于默克制药公司有意淡化了万络的风险，在万络退出市场之后，投资者在股市中损失了数十亿美元。
Investors are also suing Merck, saying it played down the risks of Vioxx and cost them billions of dollars in stock value after the drug was removed from the market.
投资者表示，他们也正在起诉默克制药公司。由于默克制药公司有意淡化了万络的风险，在万络退出市场之后，投资者在股市中损失了数十亿美元。
Investors are also suing Merck, saying it played down the risks of Vioxx and cost them billions of dollars in stock value after the drug was removed from the market.
应用推荐